SYK Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 14.18% compared to Stryker Corp.'s net margin of 14.91%. Stryker Corp.'s return on equity of 14.06% beat Boston Scientific Corp.'s return on equity of 12.46%.

Stryker Corp. has a consensus price target of $428.11, signalling upside risk potential of 20.66%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 30.52%. Given that Boston Scientific Corp. has higher upside potential than Stryker Corp., analysts believe Boston Scientific Corp. is more attractive than Stryker Corp..

Stryker Corp. has a beta of 0.890, which suggesting that the stock is 11.047% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

Stryker Corp. has a quarterly dividend of $0.84 per share corresponding to a yield of 0.95%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker Corp. pays 41.74% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker Corp. quarterly revenues are $6.1B, which are larger than Boston Scientific Corp. quarterly revenues of $5.1B. Stryker Corp.'s net income of $859M is higher than Boston Scientific Corp.'s net income of $755M. Notably, Stryker Corp.'s price-to-earnings ratio is 46.59x while Boston Scientific Corp.'s PE ratio is 51.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker Corp. is 5.62x versus 7.41x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical, Inc. has a net margin of 14.18% compared to Stryker Corp.'s net margin of 15.47%. Stryker Corp.'s return on equity of 14.06% beat Globus Medical, Inc.'s return on equity of 10.08%.

Stryker Corp. has a consensus price target of $428.11, signalling upside risk potential of 20.66%. On the other hand Globus Medical, Inc. has an analysts' consensus of $98.73 which suggests that it could grow by 11.22%. Given that Stryker Corp. has higher upside potential than Globus Medical, Inc., analysts believe Stryker Corp. is more attractive than Globus Medical, Inc..

Stryker Corp. has a beta of 0.890, which suggesting that the stock is 11.047% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.070, suggesting its more volatile than the S&P 500 by 7.046%.

Stryker Corp. has a quarterly dividend of $0.84 per share corresponding to a yield of 0.95%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker Corp. pays 41.74% of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker Corp. quarterly revenues are $6.1B, which are larger than Globus Medical, Inc. quarterly revenues of $769M. Stryker Corp.'s net income of $859M is higher than Globus Medical, Inc.'s net income of $119M. Notably, Stryker Corp.'s price-to-earnings ratio is 46.59x while Globus Medical, Inc.'s PE ratio is 28.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker Corp. is 5.62x versus 4.42x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 14.18% compared to Stryker Corp.'s net margin of 28.31%. Stryker Corp.'s return on equity of 14.06% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.

Stryker Corp. has a consensus price target of $428.11, signalling upside risk potential of 20.66%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $599.60 which suggests that it could grow by 3.86%. Given that Stryker Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Stryker Corp. is more attractive than Intuitive Surgical, Inc..

Stryker Corp. has a beta of 0.890, which suggesting that the stock is 11.047% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.249%.

Stryker Corp. has a quarterly dividend of $0.84 per share corresponding to a yield of 0.95%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker Corp. pays 41.74% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker Corp. quarterly revenues are $6.1B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.5B. Stryker Corp.'s net income of $859M is higher than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, Stryker Corp.'s price-to-earnings ratio is 46.59x while Intuitive Surgical, Inc.'s PE ratio is 76.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker Corp. is 5.62x versus 21.84x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings, Inc. has a net margin of 14.18% compared to Stryker Corp.'s net margin of 11.55%. Stryker Corp.'s return on equity of 14.06% beat Zimmer Biomet Holdings, Inc.'s return on equity of 6.45%.

Stryker Corp. has a consensus price target of $428.11, signalling upside risk potential of 20.66%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.04 which suggests that it could grow by 14.1%. Given that Stryker Corp. has higher upside potential than Zimmer Biomet Holdings, Inc., analysts believe Stryker Corp. is more attractive than Zimmer Biomet Holdings, Inc..

Stryker Corp. has a beta of 0.890, which suggesting that the stock is 11.047% less volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.615, suggesting its less volatile than the S&P 500 by 38.541%.

Stryker Corp. has a quarterly dividend of $0.84 per share corresponding to a yield of 0.95%. Zimmer Biomet Holdings, Inc. offers a yield of 1.07% to investors and pays a quarterly dividend of $0.24 per share. Stryker Corp. pays 41.74% of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 21.66% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker Corp. quarterly revenues are $6.1B, which are larger than Zimmer Biomet Holdings, Inc. quarterly revenues of $2B. Stryker Corp.'s net income of $859M is higher than Zimmer Biomet Holdings, Inc.'s net income of $231.2M. Notably, Stryker Corp.'s price-to-earnings ratio is 46.59x while Zimmer Biomet Holdings, Inc.'s PE ratio is 22.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker Corp. is 5.62x versus 2.22x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.